PRVB Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2023 @ 23:00):

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases...

Stats
Dzisiejszy wolumen	9.12M
Średni wolumen	2.84M
Kapitalizacja rynkowa	2.38B
EPS	$0 ( 2024-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-16.43
ATR14	$0.594 (2.38%)

Insider Trading

Date	Person	Action	Amount	type
2023-04-27	Sessa Capital (master), L.p.	Sell	15 567 497	Common Stock
2023-04-27	Wysenski Nancy	Sell	128 981	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	22 200	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	23 000	Option to Purchase Common Stock
2023-04-27	Wysenski Nancy	Sell	33 000	Option to Purchase Common Stock

INSIDER POWER
-62.73
Last 100 transactions
Buy: 11 373 023 \| Sell: 48 540 195

Wolumen Korelacja

Długi: 0.34 (neutral)

Krótki: 0.37 (neutral)

Signal:(80.187) Neutral

Provention Bio Inc Korelacja

10 Najbardziej pozytywne korelacje
KRBP	0.886
RICO	0.879
NETE	0.825
MMAC	0.812
LWAC	0.809

10 Najbardziej negatywne korelacje
SQBG	-0.875
TCAC	-0.873
TCACU	-0.869
RMRM	-0.85
SVAC	-0.82
TLGT	-0.819

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Provention Bio Inc Korelacja - Waluta/Towar

0.13
( neutral )

0.68
( moderate )

0.57
( weak )

0.45
( neutral )

-0.54
( weak negative )

-0.14
( neutral )

Provention Bio Inc Finanse

Annual	2022
Przychody:	$12.90M
Zysk brutto:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2022
Przychody:	$12.90M
Zysk brutto:	$12.38M (96.03 %)
EPS:	$-1.520

FY	2021
Przychody:	$1.40M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.810

FY	2020
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-1.880

Financial Reports:

No articles found.

Provention Bio Inc

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.